DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation (Q34280068)

1 August 2017

1 reference

title

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

2

Hoffman SL

1 reference

1 August 2017

Doolan DL

1

1 reference

1 August 2017

1 June 2001

1 reference

International Journal for Parasitology

1 August 2017

1 reference

1 August 2017

31

1 reference

1 August 2017

8

1 reference

1 August 2017

753-762

1 reference

Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Genomic tools for gene and protein discovery in malaria: toward new vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

7 January 2021

Pathogenesis of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

The complexity of protective immunity against liver-stage malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Immune effector mechanisms in malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Pathways and strategies for developing a malaria blood-stage vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Malaria DNA vaccines in Aotus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Infectious disease. Research (genomics) is crucial to attacking malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Malaria vaccines-targeting infected hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

From genomics to vaccines: malaria as a model system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Indicators of life-threatening malaria in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

The immunology of malaria infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

New insights into the epidemiology of malaria relevant for disease control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

The conserved genome organisation of non-falciparum malaria species: the need to know more

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

DNA vaccination strategies against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Rationale for the development of an engineered sporozoite malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900184-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0020-7519(01)00184-9

1 reference

1 August 2017

1 reference

PubMed ID

11403765